Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial.
The Women's Health Study trial previously reported no overall effect of low-dose aspirin (100 mg every other day) on invasive breast cancer over an average of 10 years of treatment. The present subgroup analyses further show no effects by tumour characteristics at diagnosis, suggesting that low-dose aspirin has no preventive effect on breast cancer.
Zhang
S M
SM
Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA. shumin.zhang@channing.harvard.edu
Cook
N R
NR
Manson
J E
JE
Lee
I-M
IM
Buring
J E
JE
D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D012306:Risk
D001241:Aspirin